2-羟基-6-硝基苯甲腈 | 72106-43-5

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 2-羟基-6-硝基苯甲腈
• 英文名称: 2-hydroxy-6-nitrobenzonitrile
• 英文别名: 2-cyano-3-nitrophenol；2-hydroxy-6-nitro-benzonitrile；2-Hydroxy-6-nitro-benzonitril；6-Nitro-salicylsaeure-nitril；3-Nitro-2-cyan-phenol；2-Cyan-3-nitrophenol
• CAS: 72106-43-5
• 化学式: C₇H₄N₂O₃
• mdl: MFCD18397343
• 分子量: 164.12
• InChiKey: QFZZIZQQRXJMGN-UHFFFAOYSA-N

物化性质

• 熔点：
  132-133 °C
• 沸点：
  366.6±37.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  89.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-羟基-6-硝基苯甲腈 在 sodium hydroxide 、 硫酸 、 镍 作用下， 生成 6-羟基邻氨基苯甲酸
  参考文献：
  名称：

  Justoni et al., Il Farmaco, scienza e tecnica, 1951, vol. 6, p. 849,855

  摘要：

  DOI：
• 作为产物：
  描述：

  2-ethoxy-6-nitro-benzonitrile 在 二硫化碳 、 三氯化铝 作用下， 生成 2-羟基-6-硝基苯甲腈
  参考文献：
  名称：

  Auwers; Walker, Chemische Berichte, 1898, vol. 31, p. 3041

  摘要：

  DOI：

文献信息

• METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER
  申请人：TACHDJIAN Catherine

  公开号：US20120041078A1

  公开（公告）日：2012-02-16

  The present invention includes methods of stabilizing one or more sweet enhancers when they are exposed to a light source as well as liquid compositions containing one or more sweet enhancers and one or more photostabilizers.

  本发明包括在甜味增强剂暴露于光源时稳定一个或多个甜味增强剂的方法，以及包含一个或多个甜味增强剂和一个或多个光稳定剂的液体组合物。
• Novel resorcinol ethers and anti-inflammatory and anti-allergic use
  申请人：Ciba-Geigy Corporation

  公开号：US04863942A1

  公开（公告）日：1989-09-05

  Novel 4-acylresorcinol ethers of the formula ##STR1## in which R.sub.1 represents lower alkyl, R.sub.2 represents lower alkyl, lower alkenyl or lower alkynyl, R.sub.3 represents hydrogen, lower alkoxy, trifluoromethyl or halogen, alk represents an alkylene radical, one of the radicals R.sub.4, R.sub.5 and R.sub.7 is a group of the formula --NH--C(.dbd.O)--R.sub.8, a radical R.sub.4 or R.sub.5 that is other than a group of the formula --NH--C(.dbd.0)--R.sub.8 is a radical R.sub.9 and a radical R.sub.7 that is other than a group of the formula --NH--C(.dbd.0)--R.sub.8 is a radical R.sub.10, R.sub.6 represents hydrogen, lower alkyl, halogen, trifluoromethyl, optionally esterified or amidated carboxy, cyano or lower alkanoyl, R.sub.8 represents optionally esterified or amidated carboxy, or 5-tetrazolyl, R.sub.9 represents hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl, and R.sub.10 represents hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, cyano or optionally esterified or amidated carboxy, and their salts have LTD.sub.4 -antagonistic and PLA.sub.2 -phospholipase-inhibiting properties. They can be manufactured according to methods known per se.

  该公式的小说4-酰基邻苯二酚醚化合物，其中R.sub.1代表较低的烷基，R.sub.2代表较低的烷基，较低的烯基或较低的炔基，R.sub.3代表氢，较低的烷氧基，三氟甲基或卤素，alk代表烷基基团，其中R.sub.4，R.sub.5和R.sub.7中的一个基团是--NH--C(.dbd.O)--R.sub.8的基团，除了--NH--C(.dbd.O)--R.sub.8的基团是R.sub.9的基团和除了--NH--C(.dbd.O)--R.sub.8的基团是R.sub.10的基团之外，R.sub.6代表氢，较低的烷基，卤素，三氟甲基，可选地酯化或酰胺化的羧基，氰基或较低的烷酰基，R.sub.8代表可选地酯化或酰胺化的羧基，或5-四氮唑基，R.sub.9代表氢，较低的烷基，较低的烷氧基，卤素或三氟甲基，R.sub.10代表氢，较低的烷基，较低的烷氧基，卤素，三氟甲基，氰基或可选地酯化或酰胺化的羧基，它们的盐具有LTD.sub.4-拮抗和PLA.sub.2-磷脂酶抑制性能。它们可以根据已知方法制造。
• Novel fluorinated resorcinol ethers
  申请人：Ciba-Geigy Corporation

  公开号：US04670604A1

  公开（公告）日：1987-06-02

  4-Acylresorcinol ethers of the formula ##STR1## in which R.sub.1 is lower alkyl, R.sub.2 is fluorinated lower alkyl, R.sub.3 is hydrogen, lower alkoxy, trifluoromethyl or halogen, alk is an alkylene or hydroxyalkylene radical which is uninterrupted or interrupted by oxygen, one of the radicals R.sub.4, R.sub.5 and R.sub.7 is a group of the formula --NH--C(.dbd.O)--R.sub.8, a radical R.sub.4 or R.sub.5 which differs from this is a radical R.sub.9 and a radical R.sub.7 which differs from this is a radical R.sub.10, R.sub.6 is hydrogen, lower alkyl, trifluoromethyl, halogen, carboxyl which is free, esterified or amidated, cyano or lower alkanoyl, R.sub.8 is carboxyl which is free, esterified or amidated or 5-tetrazolyl, R.sub.9 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl and R.sub.10 is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, cyano or carboxyl which is free, esterified or amidated, and their salts have antiallergic and antiinflammatory properties. They are prepared, for example, by reacting compounds of the formulae ##STR2## in which one of the radicals X.sub.5 and X.sub.6 is hydroxyl which is free or in salt form and the other is an alkoxy radical substituted by reactive esterified hydroxyl or epoxy. The invention also relates to intermediates of the formula ##STR3## in which R.sub.2 is fluorinated lower alkyl, R.sub.3 is hydrogen, lower alkoxy, trifluoromethyl or halogen and R.sub.11 is hydrogen or a group of the formula R.sub.1 --O(.dbd.O)--, in which R.sub.1 is lower alkyl, and their salts.

  公式为##STR1##的4-酰基邻苯二酚醚中，其中R.sub.1为较低的烷基，R.sub.2为氟代较低的烷基，R.sub.3为氢、较低的烷氧基、三氟甲基或卤素，alk为未受氧或被氧中断的烷基或羟基烷基基团，R.sub.4、R.sub.5和R.sub.7中的一个是--NH--C(.dbd.O)--R.sub.8的基团，与此不同的基团R.sub.4或R.sub.5是基团R.sub.9，与此不同的基团R.sub.7是基团R.sub.10，R.sub.6为氢、较低的烷基、三氟甲基、卤素、游离的、酯化的或酰胺化的羧基、氰基或较低的烷酰基，R.sub.8为游离的、酯化的或酰胺化的羧基或5-四唑基，R.sub.9为氢、较低的烷基、较低的烷氧基、卤素或三氟甲基，R.sub.10为氢、较低的烷基、较低的烷氧基、卤素、三氟甲基、氰基或游离的、酯化的或酰胺化的羧基，以及它们的盐具有抗过敏和抗炎性能。例如，通过反应下列公式的化合物制备它们：##STR2##其中X.sub.5和X.sub.6中的一个是游离的或盐形式的羟基，另一个是被反应性酯化羟基或环氧基取代的烷氧基基团。该发明还涉及公式##STR3##中的中间体，其中R.sub.2为氟代较低的烷基，R.sub.3为氢、较低的烷氧基、三氟甲基或卤素，R.sub.11为氢或R.sub.1--O(.dbd.O)--的基团，其中R.sub.1为较低的烷基，以及它们的盐。
• The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity
  作者：Rebecca Newton、Katherine A. Bowler、Emily M. Burns、Philip J. Chapman、Emma E. Fairweather、Samantha J.R. Fritzl、Kristin M. Goldberg、Niall M. Hamilton、Sarah V. Holt、Gemma V. Hopkins、Stuart D. Jones、Allan M. Jordan、Amanda J. Lyons、H. Nikki March、Neil Q. McDonald、Laura A. Maguire、Daniel P. Mould、Andrew G. Purkiss、Helen F. Small、Alexandra I.J. Stowell、Graeme J. Thomson、Ian D. Waddell、Bohdan Waszkowycz、Amanda J. Watson、Donald J. Ogilvie

  DOI：10.1016/j.ejmech.2016.01.039

  日期：2016.4

  therefore, a clinical need for more specific RET kinase inhibitors. Herein we report our efforts towards identifying a potent and selective RET inhibitor using vandetanib 1 as the starting point for structure-based drug design. Phenolic anilinoquinazolines exemplified by 6 showed improved affinities towards RET but, unsurprisingly, suffered from high metabolic clearance. Efforts to mitigate the metabolic

  受体酪氨酸激酶 RET 的失调与甲状腺髓样癌、一小部分肺腺癌、耐内分泌乳腺癌和胰腺癌有关。有几种临床批准的多激酶抑制剂将 RET 作为二级药理学，但其他活性，最显着的 KDR 抑制，会导致剂量限制性毒性。因此，临床需要更特异性的 RET 激酶抑制剂。在这里，我们报告了我们使用凡德他尼1作为基于结构的药物设计的起点来鉴定有效和选择性 RET 抑制剂的努力。酚类苯胺基喹唑啉以6为例显示对 RET 的亲和力有所提高，但不出所料，代谢清除率高。减轻苯酚代谢倾向的努力导致发现侧翼取代基不仅提高了肝细胞稳定性，而且还可以显着提高选择性。最终确定了36 个；一种有效的 RET 抑制剂，对 KDR 的选择性大大提高。
• Synthesis of [[(naphthalenylmethoxy)- and -(quinolinylmethoxy)phenyl]amino]oxoalkanoic acid esters. A novel series of leukotriene D4 antagonists and 5-lipoxygenase inhibitors
  作者：John H. Musser、Dennis M. Kubrak、Joseph Chang、Alan J. Lewis

  DOI：10.1021/jm00158a019

  日期：1986.8

  A series of novel [[(naphthalenylmethoxy)- and [[(quinolinylmethoxy)phenyl]amino]oxoalkanoic acid esters have been prepared. These compounds were tested as inhibitors of rat polymorphonuclear leukocyte (PMN) 5-lipoxygenase (LO) in vitro and as inhibitors of ovalbumin (OA) and leukotriene D4 (LTD4) induced bronchospasm in the guinea pig (GP) in vivo. Many naphthalenyl compounds were potent inhibitors

  已经制备了一系列新型的[[（（萘基甲氧基）-和[[（喹啉基甲氧基）苯基]氨基]氧代链烷酸酯。在体外测试了这些化合物作为大鼠多形核白细胞（PMN）5-脂氧合酶（LO）的抑制剂以及卵白蛋白（OA）和白三烯D4（LTD4）诱导的豚鼠（GP）支气管痉挛的抑制剂。GP中许多萘化合物是5-LO的有效抑制剂，而一些喹啉基化合物是LTD4介导的支气管痉挛的有效抑制剂。最有效的萘化合物4-[[[3-（2-萘甲氧基甲氧基）苯基]羟基氨基] -4-氧代丁酸甲酯（6v）在5-LO分析中的IC50为0.6 microM。体内最有效的化合物4-[[[3-（2-喹啉基甲氧基）苯基]羟基氨基] -4-氧代丁酸甲酯（6e）的ED50为3.3 mg / kg，为27。分别针对LTD4-和OA引起的支气管痉挛分别为4 mg / kg（十二指肠内）。当作为LTD4诱导的分离GP气管螺旋带收缩的拮抗剂进行测试时，显示6e是竞争性抑制剂，pKB值为5